SurvivorNet on MSN
ASCO 2026: A major prostate cancer trial shows drug can keep high-risk disease from returning for longer
Data from the PROTEUS trial showed that adding a hormone-blocking pill called apalutamide to standard hormone therapy, both ...
By Sneha S K May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six ...
Thousands of men with advanced prostate cancer could soon live longer thanks to a treatment which cuts the risk of the ...
By doing hormone therapy up front in prostate cancer cases, the hope was to shrink the relapse rate after surgery. Results ...
Early-stage trials of a new drug for advanced prostate cancer have yielded "remarkable" results, according to medical experts. This innovative treatment, an immunotherapy designed to harness the ...
Chemotherapy uses medicines to kill fast-growing cells (like cancer cells) or to keep them from dividing (which is how cancers grow). It is a systemic treatment which means the medicines will travel ...
A proof-of-concept study has created a blueprint for producing prostate cancer treatment more efficiently. Researchers at the ...
See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. Those with prostate cancer that returns after surgery or radiation—and ...
Johnson & Johnson's Erleada drug, combined with hormone therapy, significantly reduces the risk of prostate cancer spread and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results